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How Stricter E-Cigarette Regulations
Will Keep The Traditional Cigarette
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Tyler Manuel*

ABSTRACT
First harvested for export in 1612, tobacco has remained a large, and controversial,
part of the United States’ identity. In 1966, 42.6% of the American population
smoked cigarettes. Currently, cigarette usage rate is around 14%, its lowest rate
ever. Even with this sharp decline, cigarettes remain the number one cause of preventable deaths in the United States resulting in approximately 480,000 deaths per
year. Nicotine, the active ingredient in tobacco, is an addictive drug, and many treatments exist for those attempting to quit. Recent studies have shown, however, that
electronic nicotine delivery systems, more commonly known as “vapes” or “e-cigarettes”, are more effective than the other forms of commonly used cigarette cessation devices. E-cigarettes have been marked by their own controversy, however, as
they have shown to be exceedingly popular among adolescents. Due to the high
underage use, many states began implementing their own regulations or bans on ecigarettes, with the federal government eventually stepping in to attempt to limit
underage use. These attempts may have the consequential side-effects of leading
those using e-cigarettes as a cessation device to return to using traditional cigarettes
and adding a barrier to current cigarette smokers wanting to quit. To remedy this, I
propose that the United States Food and Drug Administration (“FDA”) provide ecigarettes with a specialized Over-the-Counter monograph that would allow adults
access to what has shown to be an incredible cigarette cessation tool, while also
limiting accessibility to minors.
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INTRODUCTION
A. The FDA’s Regulatory Authority of E-Cigarettes

In 1996, the Food and Drug Administration (“FDA”) attempted to assert jurisdiction over the regulation of tobacco products by claiming that nicotine is covered
under the “drug” definition in the Federal Food, Drugs, and Cosmetics Act
(“FDCA”).1 If so, cigarettes and smokeless tobacco are drug-device combinations
as they are devices delivering nicotine to the body.2 The FDA then promulgated
regulations regarding the promotion, labeling, and accessibility of tobacco products
in an attempt to decrease nicotine usage.3 In response to these regulations, tobacco
manufacturers, retailers, and advertisers filed suit against the FDA, leading to the
2000 Supreme Court case Food and Drug Administration v. Brown & Williamson
Tobacco Corp. (“Brown”).4 In Brown, the Court held that “the FDA’s claim to
jurisdiction contravenes the clear intent of Congress” 5 because Congress had already spoken directly on the issue of tobacco product regulation by enacting tobacco specific legislation that did not involve the FDA. 6 Examples of such Congressional action include the Federal Cigarette Labeling and Advertising Act
(“FCLAA”), which regulates cigarettes and “little cigars”, 7 and the Comprehensive
Smokeless Tobacco Health Education Act of 1986 (“CSTHEA”), which regulates
smokeless tobacco.8 The Court reasoned that since one main purpose of the FDCA
is to ensure that FDA regulated products are “‘safe’ and ‘effective’ for [their] intended use,”9 the FDA would have to ban tobacco products, which are “the single
leading cause of preventable death in the United States.”10 Further, the risk tobacco
products posed to public health precludes a finding that tobacco products can be
safe for their intended use.11 Since the adverse health effects of tobacco products
were already well known when Congress enacted the FCLAA and the CSTHEA,12
and Congress still decided to regulate the products as oppose to banning them, the
Court concluded that it would be directly adverse to congressional intent for the

1. Food, Drug, and Cosmetic Act, ch. 675, Ch. II, § 201(g)(1), Pub. L. No. 111-31., 123 Stat. 1807
(1938) (codified as amended at 21 U.S.C. § 321(g)(1) (2021)). (“The term ‘drug’ means (A) articles
recognized in the official United States Pharmacopœia, official Homœopathic Pharmacopœia of the
United States, or official National Formulary, or any supplement to any of them; and (B) articles intended
for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals;
and (C) articles (other than food) intended to affect the structure or any function of the body of man or
other animals; and (D) articles intended for use as a component of any article specified in clause (A),
(B), or (C). . . .”).
2. Food and Drug Admin. v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 127 (2000), superseded by statute, Family Smoking Prevention and Tobacco Control Act of 2009, Pub. L. No. 111-31,
123 Stat. 1776, as recognized in Big Time Vapes, Inc. v. FDA, 963 F. 3d 436 (5th Cir. 2020).
3. See id. at 128.
4. Id. at 129-30.
5. Id. at 132.
6. See 15 U.S.C. § 1331 (2018).
7. See id.
8. Brown, 529 U.S. at 156; 15 U.S.C. § 4401 (2018).
9. Brown, 529 U.S. at 133-34; see also 21 U.S.C. § 393(b)(2) (2018).
10. Brown, 529 U.S. at 134-135.
11. See id. at 135.
12. See id. at 138.
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FDA to have jurisdiction over tobacco products as the agency would be required to
ban them under the FDCA.13
The FDA’s authority to regulate tobacco products comes from the enactment
of the Family Smoking Prevention and Tobacco Control Act (“TCA”) on June 22,
2009, which amended the FDCA to include tobacco products.14 Before this, tobacco
products were only covered by the FDA in instances where the manufacturers made
health claims about their tobacco product.15
Although the TCA gave the FDA jurisdiction over tobacco products, the
amendment did not necessarily mean that the FDA could outright ban tobacco products for lack of safety, as may be surmised by Brown. The TCA gave the FDA
jurisdiction to regulate all tobacco products as tobacco products, not as drugs or
medical devices.16 As such, the FDA no longer has to rely on the argument that such
products are a drug or device to gain jurisdictional authority.17
The TCA “excludes from the meaning of ‘tobacco product’ any ‘article that is
a drug under 21 U.S.C. § 321(g)(1), a device under 21 U.S.C. § 321(h), or a combination product described in 21 U.S.C. § 353(g).”18 As discussed in Brown, if the
tobacco product is deemed to be a drug, a device, or a combination product, then
the tobacco product must be banned under the FDCA. 19 This exclusion provision
would be satisfied when a manufacturer of a tobacco product markets the product
in a way that is outside the existing marketing standards set by tobacco specific
legislation,20 such as a claim of the product being a weight-loss aid or as a cessation
device from traditional cigarettes.21
The FDA defines an e-cigarette as “an electronic device that delivers e-liquid22
in aerosol form into the mouth and lungs when inhaled.” 23 Under this definition,
there are two types of devices, open e-cigarettes, devices where the user can refill
with their own e-liquid, and closed e-cigarettes, which are not intended to be refilled
and include disposable e-cigarettes and replaceable cartridge based devices.24 The
13. See id. at 137-39.
14. Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems: Guidance for
Industry, FOOD AND DRUG ADMINISTRATION: CENTER FOR TOBACCO PRODUCTS 3 (June 2019),
https://www.fda.gov/media/127853/download [hereinafter Premarket Tobacco Product Applications].
15. See Federal Regulation of Tobacco: A Summary, TOBACCO CONTROL LEGAL CONSORTIUM 2
(July 2009), https://www.publichealthlawcenter.org/sites/default/files/resources/tclc-fda-summary.pdf.
16. See generally 21 U.S.C. §393(b)(2) (providing guidelines when tobacco products could be regulated).
17. See generally id. (eliminating the drug or device requirement for regulation).
18. Smoking Everywhere, Inc. v. U.S. Food and Drug Admin., 680 F. Supp. 2d 62, 67 (D.D.C.
2010), aff’d sub nom. Sottera, Inc. v. Food & Drug Admin., 627 F.3d 891 (D.C. Cir. 2010).
19. Food and Drug Admin. v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 142 (2000), superseded by statute, Family Smoking Prevention and Tobacco Control Act of 2009, Pub. L. No. 111-31,
123 Stat. 1776, as recognized in Big Time Vapes, Inc. v. FDA, 963 F. 3d 436 (5th Cir. 2020).
20. See e.g. Federal Cigarette Labelling and Advertising Act (FCLAA)., Pub. L. No. 89-92, 79 Stat.
282 (1965) (codified as amended at 15 U.S.C. § 1331 (2018)); Comprehensive Smokeless Tobacco
Health Education Act (CSTHEA), Pub. L. No. 99-252, 100 Stat. 30 (1986) (codified as amended at 15
U.S.C. § 4401 (2018)).
21. See Smoking Everywhere, 680 F. Supp. 2d at 67-68.
22. Premarket Tobacco Product Applications, supra note 14, at 6 (Definition of e-liquid: “e-liquids
include liquid nicotine, nicotine- containing liquids (i.e., liquid nicotine combined with colorings, flavorings, and/or other ingredients), and liquids that do not contain nicotine or other material made or
derived from tobacco, but that are intended or reasonably expected to be used with or for the human
consumption of a tobacco product.”)
23. Id.
24. Id.
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FDA classifies both e-cigarettes and e-liquids as covered under the general term
Electronic Nicotine Delivery System (“ENDS”).25
As ENDS were not explicitly included in the TCA, it was unclear whether they
were considered tobacco products and were to be regulated the same as traditional
tobacco products, or as drug-device combination.26 In the 2012 case Smoking Everywhere v. U.S. Food and Drug Administration (Smoking Everywhere), American
e-cigarette distributers Smoking Everywhere and NJOY sued the FDA as a result
of their 2008 refusal to allow importation of e-cigarettes.27 The FDA contended that
the imported e-cigarettes were “intended to affect the structure or function of the
body, and to prevent, mitigate, or treat the withdrawal symptoms of nicotine addiction,”28 making the e-cigarettes an unapproved drug-device combination under the
FDCA.29 The FDA argued that e-cigarettes were outside the scope of Brown & Williamson as neither the FLCAA nor the CSTHEA applied to e-cigarettes, and were
not covered by the TCA.30 The court responded that “this argument is bootstrapping
run amuck”31 and that Congress intended the TCA to cover non-traditional tobacco
products because in the act they both single out traditional tobacco products and use
the broader term “tobacco product.”32
As a result of this clarification, on May 10, 2016 the FDA issued a final rule
clarifying that their authority extends to any product that “meet(s) the statutory definition of ‘tobacco product’ in section 201(rr) of the FD&C Act,” which includes
ENDS products.33 Any new tobacco product, as defined under FDCA § 910,34 must
undergo premarket review through either the manufacturer showing that the product
is exempt from premarket review, the product is substantially equivalent to a nonnew tobacco product, or filing a premarket tobacco application (PMTA). 35 In August of 2017, the FDA issued guidance announcing that it will not enforce the premarket review provision for ENDS products until 2022.36 This guidance was vacated in the 2019 case American Academy of Pediatrics v. FDA amidst the backdrop
of an alarming adolescent usage rate of ENDS products and a new lung disease
affecting e-cigarette users.37 The court ordered manufacturers to submit their
25. Id.
26. See id. at 63-67.
27. Id.
28. Id. at 67-68.
29. Id. at 68.
30. Id. at 71.
31. Id. at 70.
32. Id. at 71.
33. Id. at 3.
34. “Any tobacco product that was not commercially marketed in the United States as of February 15,
2007; or any modification of a tobacco product where the modified product was commercially marketed
in the United States after February 15, 2007,” Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910,
Pub. L. No. 111-31., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j) (2019)).
35. See 21 U.S.C. § 387(j)(2) (2019).
36. Am. Acad. of Pediatrics v. Food and Drug Administration, 379 F. Supp. 3d 461, 468 (D. Md.
2019).
37. Id.; see also Teresa W. Wang et al., E-Cigarette Use Among Middle and High School Students –
United States, 2020, 69 MORBIDITY & MORTALITY WEEKLY REPORT 1310, 1310 (Sep. 18, 2020) (stating
that “[i]n 2020, approximately one in five high school students and one in 20 middle school students
currently used e-cigarettes. By comparison, in 2019, 27.5% of high school students (4.11 million) and
10.5% of middle school students (1.24 million) reported current e-cigarette use.”); E-cigarette or Vaping
Product Use-Associated Lung Injury (EVALI), YALE MEDICINE, https://www.yalemedicine.org/conditions/evali/ (last visited April 1, 2021) [hereinafter E-cigarette or Vaping Product Use-Associated Lung
Injury (EVALI)]; FDA Issues Proposed Rule for Premarket Tobacco Product Applications as Part of
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PMTAs by May 12, 2020.38 This May 12th deadline was then extended to September 9, 2020 to provide manufactures relief from varying complications in filling out
their PMTAs stemming from the coronavirus pandemic.39

B. The Current E-Cigarette Market
E-cigarettes were invented by Chinese pharmacist, Hon Lik, in 2003, and introduced to the American market in 2007.40 In the 13-years that these devices have
been on the U.S. market, e-cigarettes have grown into a 4.2 billion USD industry as
of 2018, with an expected compound annual growth rate of 24.1% from 2019 to
2025, and a 12.41 billion USD valuation worldwide as of 2019. 41 In recent years,
there has been a staggering increase in adolescent use of e-cigarettes, with a 2020
study revealing that “19.6% of high school students (3.02 million) and 4.7% of middle school students (550,000) reported current e-cigarette use.”42
Although experts generally agree that ENDS products are less harmful than
traditional cigarettes, the long-term effects of the products are still unclear.43 In August of 2019, the Centers for Disease Control (“CDC”) identified a lung disease,
later named EVALI, that was linked to the use of e-cigarettes.44 By February 18,
2020, there were a total of 2,807 hospitalizations or deaths in the United States resulting from EVALI, and the American Medical Association urged the public to
avoid the use of e-cigarettes entirely.45 Amidst this outbreak and the high rate of

Commitment to Continuing Strong Oversight of E-cigarettes and Other Tobacco Products , FOOD AND
DRUG ADMINISTRATION, (Sep. 20, 2019) https://www.fda.gov/news-events/press-announcements/fdaissues-proposed-rule-premarket-tobacco-product-applications-part-commitment-continuing-strong.
38. Am. Acad. of Pediatrics, 379 F. Supp. 3d at 468.
39. See Coronavirus (COVID-19) Update: Court Grants FDA’s Request for Extension of Premarket
Review Submission Deadline for Certain Tobacco Products Because of Impacts from COVID-19, FOOD
AND DRUG ADMINISTRATION (April 23, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-court-grants-fdas-request-extension-premarket-review-submission-deadline.
40. Rachel Grana et al., Background Paper on E-cigarettes (Electronic Nicotine Delivery Systems),
CENTER FOR TOBACCO CONTROL RESEARCH AND EDUCATION 6 (Dec. 2013), https://escholarship.org/uc/item/13p2b72n#page=6.
41. GRAND VIEW RESEARCH, U.S. E-cigarette And Vape Market Size, Share & Trends Analysis Report By Component, By Distribution Channel, By Product (Rechargeable, Disposable, Modular), And
Segment Forecasts, 2019 – 2025, (June 2019) https://www.grandviewresearch.com/industry-analysis/ecigarette-vaping-market; GRAND VIEW RESEARCH, E-cigarette And Vape Market Size, Share & Trends
Analysis Report By Product (Disposable, Rechargeable), By Component (Vape Mod, E-liquid), By Distribution Channel, And Segment Forecasts, 2020 – 2027, (Feb. 2020) https://www.grandviewresearch.com/industry-analysis/e-cigarette-vaping-market.
42. Wang et al., supra note 37, at 1310.
43. See generally David T. Levy et al., Potential Deaths Averted in USA by Replacing Cigarettes With
E-cigarettes, TOBACCO CONTROL 2018:27:18, 18 (2018) (concluding “[t]he tobacco control community
has been divided regarding the role of e-cigarettes in tobacco control. Our projections show that a strategy of replacing cigarette smoking with vaping would yield substantial life year gains, even under pessimistic assumptions regarding cessation, initiation and relative harm”); KATHLEEN STRATTON ET AL.,
NAT’L ACADEMIES OF SCI., ENG’G, & MED., PUBLIC HEALTH CONSEQUENCES OF E-CIGARETTES, 15-16
(2018).
44. E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI), supra note 37.
45. See Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping, CENTERS FOR DISEASE
CONTROL (Feb. 25, 2020), https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lungdisease.html#cdc-recommends [hereinafter Outbreak of Lung Injury Associated with E-cigarette Use];
Patrice A. Harris, M.D., M.A., AMA Urges Public to Avoid E-cigarette Use Amid Lung Illness Outbreak,
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adolescent use of ENDS, nine states and more than 250 cities enacted or planned ecigarette bans or restrictions.46 The federal government also took action, with President Trump announcing a ban on the sale of flavored e-liquids except for tobacco
and menthol for cartridge based devices and raising the minimum age to buy tobacco products from 18 to 21.47 Further research into EVALI, however, later revealed that the disease was not caused by traditional e-cigarettes, but by Vitamin E
acetate found in e-cigarettes containing THC.48
The actions taken by federal and state governments to decrease adolescent usage of e-cigarettes seem to have been effective. The usage rates of 19.6% and 4.7%
of high schoolers and middle schoolers in 2020, respectively, decreased from the
2019 usage rates of 27.5% of high schoolers and 10.5% of middle schoolers.49 These
actions are not without consequence, as stricter regulations and outright bans on
these products may lead to an increase in traditional cigarette smokers and a decrease in cigarette cessation rates.50 Rather than imposing stricter limitations or banning these products, I propose providing an easier new drug pathway to market for
ENDS products along with providing the current tobacco product pathways. This
would allow ENDS to be marketed as cessation devices, with the flavored ENDS
being the most common among adults attempting to quit traditional cigarettes,51
while still reducing adolescent access to the devices.

AMERICAN MEDICAL ASSOCIATION (Sep. 9, 2019), https://www.ama-assn.org/press-center/ama-statements/ama-urges-public-avoid-e-cigarette-use-amid-lung-illness-outbreak.
46. See Terry Turner, Juul Ban, DRUGWATCH, https://www.drugwatch.com/e-cigarettes/juul-ban/
(last modified March 16, 2021).
47. Dan Vergano, Trump Just Announced A Nationwide Ban Of Flavored Vape Cartridges Except
Tobacco And Menthol, BUZZFEED NEWS (Jan. 2, 2020 1:43 PM), https://www.buzzfeednews.com/article/danvergano/trump-juul-flavor-ban.
48. See Outbreak of Lung Injury Associated with E-cigarette Use, supra note 45; Colin Poitras, Rates
of E-cigarette and Marijuana Use Not Associated With Larger Outbreaks of Vaping-Related Lung Injuries, YSPH Study Finds, YALE SCHOOL OF PUBLIC HEALTH (Aug. 25, 2020), https://publichealth.yale.edu/news-article/26879/.
49. Wang et al., supra note 37, at 1310.
50. See generally Peter Hajek et al., A Randomized Trial of E-Cigarettes Versus Nicotine-Replacement
Therapy, 380 N. ENGL. J. MED. 629, 629 (Jan. 30, 2019) (concluding “[e]-cigarettes were more effective
for smoking cessation than nicotine-replacement therapy, when both products were accompanied by behavioral support”); Leonie S. Brose et al., Associations Between Vaping and Relapse to Smoking: Preliminary Findings From a Longitudinal Survey in the UK, 16:76 HARM REDUCTION J. (Dec. 30, 2019),
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0344-0
(concluding
“[r]elapse to smoking is likely to be more common among ex-smokers vaping infrequently or using less
advanced devices); Guy Bentley, Cigarette Sales Increase as Vaping Bans Push People Back to Smoking, REASON FOUNDATION (Aug. 24, 2020), https://reason.org/commentary/cigarette-sales-increase-asvaping-bans-push-people-back-to-smoking/ (discussing potential results of the San Francisco ban on flavored tobacco products potentially leading to loss in revenue and increase in traditional cigarette sales.)
51. Shannon Gravely, et al., The Association of E-cigarette Flavors With Satisfaction, Enjoyment, and
Trying to Quit or Stay Abstinent From Smoking Among Regular Adult Vapers From Canada and the
United States: Findings From the 2018 ITC Four Country Smoking and Vaping Survey, 22:10 NICOTINE
AND TOBACCO RESEARCH 1831, 1834 (May 25, 2020).
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II. EXPLORING THE PATHWAYS TO MARKET

A. Premarket Tobacco Product Applications and Substantial
Equivalence
New tobacco products can enter the market in one of three ways: (1) by showing that the product is substantially equivalent to a previously approved tobacco
product, (2) by showing that the product is exempt from showing substantial equivalence, or (3) completion and acceptance of a premarket tobacco application
(“PMTA”).52
PMTA’s are required for any “new tobacco product”53 that a company introduces or delivers for introduction into interstate commerce. 54 For a PMTA to be
accepted, a manufacturer must show that allowing their new tobacco product on the
market would be “appropriate for the protection of the public health.” 55 In determining whether the product is appropriate, the FDA takes into account “(A) the
increased or decreased likelihood that existing users of tobacco products will stop
using such products; and (B) the increased or decreased likelihood that those who
do not use tobacco products will start using such products.” 56 The manufacturing
process of the product must also conform to good manufacturing practices under
FDCA § 906 (e).57 A manufacturer’s labeling cannot be false or misleading, and
must conform to the tobacco product standards found in FDCA § 907 or provide
adequate information behind any change from the standards.58
Virtually all ENDS are expected to reach the market through PMTA’s, due to
the difficulty in identifying predicate ENDS products necessary for the substantial
equivalence pathways.59 To show substantial equivalence, ENDS manufacturers
would need to identify a predicate tobacco product that was “commercially marketed (other than for test marketing) in the United States as of February 15, 2007.” 60
52. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910, Pub. L. No. 111-31., 123 Stat. 1807 (1938)
(codified as amended at 21 U.S.C. § 387(j) (2019)).
53. A new tobacco product is defined as “(A) any tobacco product (including those products in test
markets) that was not commercially marketed in the United States as of February 15, 2007; or (B) any
modification (including a change in design, any component, delivery, or form of nicotine, or any other
additive or ingredient) of a tobacco product where the modified product was commercially marketed in
the United States after February 15, 2007.” Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, §
910(a)(1)(A)-(B), Pub. L. No. 111-31., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j)
(a)(1)(A)-(B) (2019)).
54. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910, Pub. L. No. 111-31., 123 Stat. 1807 (1938)
(codified as amended at 21 U.S.C. § 387(j) (2019)).
55. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(2)(A), Pub. L. No. 111-31., 123 Stat.
1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(c)(2)(A) (2019)).
56. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(4)(A)-(B), Pub. L. No. 111-31., 123 Stat.
1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(c)(4)(A)-(B) (2019)).
57. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(2)(B), Pub. L. No. 111-31., 123 Stat.
1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(c)(2)(B) (2019)).
58. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(2)(C)-(D), Pub. L. No. 111-31., 123 Stat.
1807 (1938) (codified as amended at 21 U.S.C. § 387(j) (c)(2)(C)-(D) (2019)).
59. See generally Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(a)(1)(A)-(B), Pub. L. No.
111-31., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j) (a)(1)(A)-(B) (2019) (indicating a predicate product existed before 2007); Grana et al., supra note 40 (indicating that E-cigarettes
did not make it to American Markets until 2007).
60. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(a)(2)(A)(i)(I), Pub. L. No. 111-31., 123
Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(a)(2)(A)(i)(I) (2019)).
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Since modern e-cigarettes that could potentially be used as a predicate product to
make a showing of substantial equivalence were not introduced into the American
market until 2007, this is a virtually impossible showing to make.61 ENDS manufacturers likely could not argue that they are exempt from making a showing of
substantial equivalence as the exemptions still require the locating of a predicate
tobacco product that was commercially marketed as of February 15, 2007.62 This
only leaves ENDS manufacturers with the PMTA process pathway to the market if
they want to distribute their product as a tobacco product.
As the September 9, 2020 deadline for ENDS manufactures to submit their
PMTA’s drew closer, the cost of PMTA’s came under heavy criticism from the
ENDS industry.63 The FDA contended that completion of a PMTA would cost a
manufacturer around $117,00 to $466,000, but this was considered a low estimate
by those in the industry, with Amanda Wheeler, vape store owner and vice president
of Rocky Mountain Smoke-Free Alliance,64 estimating far more for these application.65 And Joe Teller, category management director for Swedish Match, who completed eight PMTA’s for their General Snus line of smokeless tobacco stating that
“[the cost] was more than what we thought for . . . PMTA.” 66 The high cost on the
companies stem from the FDA considering every different flavor variant and nicotine strength, and combination thereof, as a different tobacco product, and thus
needing a separate PMTA.67

B. New Drug Applications
If the manufacturer does not want to distribute their product as a tobacco product, there is also the option of distributing the tobacco product as a drug by going
through the drug pathway to market.68 For ENDS manufacturers, this is currently
not a viable option.69 Despite the shown benefits of ENDS products as tools for
cigarette cessation, ENDS that claim health benefits would be considered an unapproved drug-device combination, and would have to undergo the requisite

61. See generally Grana et al., supra note 40 (indicating that E-cigarettes did not make it to American
Markets until 2007).
62. See generally Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 905(j)(3)(A), Pub. L. No. 11131., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(e)(j)(3)(A)(2019) (giving the requirements to be exempt from such applications).
63. See Michael McGrady, As the PMTA Deadline Looms, the Vaping Industry Faces Potential Disaster, INSIDE SOURCES (Sep. 3, 2020) https://www.insidesources.com/as-the-pmta-deadline-looms-thevaping-industry-faces-potential-disaster/.
64. Rocky Mountain Smoke-Free Alliance is a not-for-profit trade organization that represents small
business owners and manufactures of ENDS in Colorado. See Advocating for Vapor Businesses is OUR
business!, ROCKY MOUNTAIN SMOKE-FREE ALLIANCE, https://www.rmsfa.org/ (last visited April 2,
2021); Meet Our Board, ROCKY MOUNTAIN SMOKE-FREE ALLIANCE, https://www.rmsfa.org/meet-ourboard (last visited April 2, 2021).
65. McGrady, supra note 63.
66. Melissa Vonder Haar, 6 Insights From CSP’s Tobacco Update Webinar, CSP DAILY NEWS (May
25, 2016), https://www.cspdailynews.com/tobacco/6-insights-csps-tobacco-update-webinar#page=4.
67. U.S. FOOD & DRUG ADMIN., Commonly Asked Questions: About the Center for Tobacco Products,
(July 10, 2020), https://www.fda.gov/tobacco-products/about-center-tobacco-products-ctp/commonlyasked-questions-about-center-tobacco-products.
68. See infra notes 70-74 and accompanying text.
69. See infra notes 75-76 and accompanying text.
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premarket review before they are allowed to reach the market. 70 Whether a drugdevice combination product goes through the drug regulatory pathway or the device
regulatory pathway depends on which part of the combination, the drug or device,
contributes the most to the product’s intended therapeutic effect. 71 For ENDS products that claim smoking cessation benefits, the drug product (the e-liquid) provides
the claimed therapeutic effect, while the device portion is used to deliver the drug
product.72 FDCA § 505(a) states that “no person shall introduce or deliver for introduction into interstate commerce any new drug”73 without an approved New Drug
Application (“NDA”), with a new drug being defined as a drug that is “not generally
recognized. . . as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling thereof.”74 Thus, an ENDS product that claims
to be useful in smoking cessation would be a new drug subject to an NDA due to
the products not being generally recognized as safe and effective for use as a smoking cessation tool.
NDA’s are even more costly than PMTA’s, with an estimated cost of $2.8 billion, as they have much stricter criteria for acceptance.75 For an NDA to be approved, the application needs to contain separate sections for clinical data on the
drugs pharmacodynamics, efficacy, and safety; data from human pharmacokinetic
studies; nonclinical studies; a full description of the manufacturing controls used;
and the patent information of the product.76 The time and cost necessary for an NDA
is only feasible for large tobacco corporations and preclude most manufacturers
from using this route.

C. Over-The Counter Monographs
A potential third option for ENDS products to reach the market is through the
use of an over-the-counter monograph (“OTC” monograph), which is what allows
products such as nicotine gum and transdermal nicotine patches to be sold without
a prescription.77 OTC monographs list the claims, labeling, dosages, and active ingredients of a product, and if the product matches everything on the list, allows it
to be sold over-the-counter without a prescription.78 Drugs that are given OTC
70. See generally Smoking Everywhere Inc. v. U.S. Food and Drug Admin., 680 F.Supp.2d, 62, 63-71
(2018); Hajek, supra note 50; Premarket Tobacco Product Applications, supra note 14, at 9; U.S. FOOD
& DRUG ADMIN., Smoking Cessation and Related Indications: Developing Nicotine Replacement
Therapy Drug Products, 3–4, (Feb. 2019), https://www.fda.gov/media/121308/download [hereinafter
Smoking Cessation and Related Indications].
71. 21 USC 353(g)(1)(C) (2018).
72. Smoking Cessation and Related Indications, supra note 70, at 4.
73. Food, Drug, and Cosmetic Act, ch. 675, Ch. V, § 505(a), Pub. L. No. 111-31., 123 Stat. 1807
(1938) (codified as amended at 21 U.S.C. § 355(a) (2018).
74. Food, Drug, and Cosmetic Act, ch. 675, Ch. II, § 201(9), Pub. L. No. 111-31., 123 Stat. 1807
(1938) (codified as amended at 21 U.S.C. § 3521(p) (2018).
75. See generally, Joseph A. DiMasi et al., Innovation in the Pharmaceutical Industry: New estimates
of R&D costs, 47 J. OF HEALTH ECON. 20, 28 (May, 2016) (discussing the costs of development and
clinical trial of drugs).
76. Food, Drug, and Cosmetic Act, ch. 675, Ch. V, § 505(b), Pub. L. No. 111-31., 123 Stat. 1807
(1938) (codified as amended at 21 U.S.C. § 355(b) (2021).
77. See U.S. FOOD & DRUG ADMIN., Over-the-Counter (OTC) Drug Monograph Process, (Sept.
3, 2020), https://www.fda.gov/drugs/over-counter-otc-drug-monograph-process [hereinafter Drug Monograph Process].
78. See id.
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monographs are generally regarded as safe and effective, meaning that they are not
considered a “new drug” under FDCA 201(p), and do not require an NDA. 79 As of
the CARES Act, signed into law on March 27, 2020, the OTC monograph process
is no longer subject to notice-and-comment rulemaking, and instead has adopted an
administrative order process by which an order to add, remove, or change a monograph can be either initiated directly by the FDA or requested by a company. 80 The
monograph is then reviewed by the FDA, and if accepted, codified in the Code of
Federal Regulations.81 Once finalized, a company can market a drug that has an
OTC monograph without going through the premarket approval process. 82
Usually, drugs that are given an OTC monograph were first prescription-only
(Rx), and the manufacturer requested approval for OTC marketing. 83 An Rx-toOTC switch requires the FDA to “look at the safety and effectiveness of the product,
the benefit-to-risk ratio, and whether the labeling can be written in such a way that
consumers can use the products safely without the intervention of a healthcare provider.”84 Individual drugs may also be granted OTC status, but not given an OTC
monograph, as is the case with the current FDA approved OTC nicotine replacement therapies (“NRT”).85 Each of the OTC NRT’s (nicotine gum, transdermal nicotine patches, and nicotine lozenges), became OTC through an Rx-to-OTC switch,
meaning they originally went through the NDA pathway.86

III. AN OVER-THE-COUNTER MONOGRAPH FOR ENDS
A. Benefits of an OTC Monograph
An OTC monograph pathway for ENDS products would benefit manufacturers, consumers, and public health more than the PMTA pathway or the NDA pathway. Research has also shown that ENDS are more effective cigarette cessation
tools than NRTs.87 A 2019 study published in the New England Journal of Medicine
compared the cigarette cessation rates of various NRTs to ENDS and concluded
that ENDS were more effective cigarette cessation tools than NRTs. 88 The study
found that “the 1-year abstinence rate was 18.0% in the e-cigarette group, as compared with 9.9% in the nicotine-replacement group.”89 Researchers also generally

79. See id.
80. Id.
81. For the general provisions and administrative procedures regarding recognition of over-the-counter drug, see 21 C.F.R. § 330.1¬ (2020) – § 330.15 (2020).
82. Drug Monograph Process, supra note 77.
83. CONSUMER HEALTHCARE PRODUCTS ASS’N, https://www.chpa.org/about-consumerhealthcare/faqs/FAQs-rx-otc-switch (last visited Mar. 6, 2021).
84. Id.
85. Azim Chowdhury & Samuel Jockel, Spotlight on Tobacco | Future Developments in the Regulation of Electronic Nicotine Delivery Systems: Potential Over-the-Counter Pathway, FOOD & DRUG L.
INST.,
https://www.fdli.org/2018/10/spotlight-on-tobacco-future-developments-in-the-regulation-ofelectronic-nicotine-delivery-systems-potential-over-the-counter-pathway/ (last visited Mar. 6, 2021);
Nicotine replacement therapy, U.S. NAT’L LIBR. OF MED., https://medlineplus.gov/ency/article/007438.htm (last visited Mar. 6, 2021).
86. See Chowdhury & Jockel, supra note 85.
87. Hajek, supra note 50, at 629.
88. Id.
89. Id.
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regard ENDS as safer than traditional cigarettes.90 A 2017 study on the potential
deaths averted in the United States by switching from traditional cigarettes to
ENDS, under both pessimistic and optimistic models, found that “replacement of
cigarette by e-cigarette use over a 10-year period yields 6.6 million fewer premature
deaths with 86.7 million fewer life years lost in the Optimistic Scenario. Under the
Pessimistic Scenario, 1.6 million premature deaths are averted with 20.8 million
fewer life years lost.”91
The benefits that an OTC monograph provides can be sorted into three categories: price, effectiveness as a cessation tool, and safety.

i. Price
One benefit of a monograph would be the potential to provide for a lower barrier to entry for manufacturers entering into the ENDS market because each individual product would no longer require premarket approval.92 Not needing premarket approval means that the monograph would be both a cheaper and more reliable pathway to market, as the manufacturer would not have to make the various
costly showings required by PMTAs or NDAs. 93 Instead, ENDS manufacturers
would only need to match the contents of the monograph to reach the market.94 This
lower entry barrier would likely lead to more competition in the market, as fewer
companies would be forced out of the industry under a monograph than the current
PMTA pathway.95 Easier access to the industry and more competition means that
ENDS would likely be cheaper for consumers. As ENDS become cheaper, they will
also become more attractive options to consumers wanting to quit smoking traditional cigarettes.

ii. Effectiveness as a Cessation Tool
An OTC monograph could allow for a wide assortment of flavors, or flavoring
ingredients to be combined at the manufacturer’s discretion, which were often the
manufacturer’s best-selling products.96 More variety in nontobacco flavored ENDS
may improve their effectiveness as a cessation device.97 A 2020 study in Nicotine
& Tobacco Research found that “[a] majority of regular vapers in Canada and the
US use nontobacco flavors. Fruit and candy flavors lead to more satisfaction and
enjoyment among users. While it does not appear that certain flavors are associated
with a greater propensity to attempt to quit smoking among concurrent users,
90. Stratton, supra note 43, at 12 (“[t]he evidence about harm reduction suggests that across a range
of studies and outcomes, e-cigarettes pose less risk to an individual than combustible tobacco cigarettes.”)
91. Levy, supra note 43, at 18.
92. See Drug Monograph Process, supra note 77.
93. See supra notes 63-74 and accompanying text.
94. See Drug Monograph Process, supra note 77.
95. See McGrady, supra note 63.
96. See Victoria Forster, Study: Juul Stopped Selling Their Fruit-Flavored Vaping Pods, With No
Effect On Overall Sales, FORBES (Apr. 17, 2020, 7:44 AM) https://www.forbes.com/sites/victoriaforster/2020/04/17/study-juul-ceasing-sales-of-fruit-flavored-e-cigarettes-had-no-effect-on-overallsales/?sh=4f346d4c4cc5 (in October 2018, fruit flavors made up one-third of all sales of Juul flavors).
97. Gravely, supra note 51, at 1831-32.
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nontobacco flavors are popular among former smokers who are exclusively vaping.” 98 Flavored ENDS products are also the most popular among adolescents, and
the limitations placed on flavored ENDS were enacted primarily to decrease adolescent usage.99 An OTC monograph, combined with other sale restrictions, could
combat this by placing limitations on where ENDS products could be sold, limiting
the accessibility of the products to minors.100

iii. Safety
Perhaps the largest benefit of an OTC monograph pathway over the PMTA
pathway for ENDS is that it would allow greater regulatory oversight over the health
and safety of the products.101 Scott Gottlieb, the previous FDA Commissioner,
stated in an interview with CNBC that:
[An] over-the-counter regulatory pathway . . . would give us many more tools
to look at both safety and benefit, and study whether or not an e-cigarette actually
does promote smoking cessation and also give us many more tools to actually study
the toxicology associated with it and see what effects it might have on the lung. 102
Although the availability of an OTC monograph for ENDS provides many clear
benefits, there are three immediately apparent issues with the pathway. The issue of
adolescent usage of ENDS, whether using ENDS to quit traditional nicotine products leads to long-term nicotine abstinence, and the barriers that are inherent to the
creation of an OTC monograph for a drug.

B. The Lingering Issue of Adolescent Use
The issue of potential adolescent use of flavored ENDS could be mitigated by
restricting the distribution of the products in ways where it would be more difficult
for the adolescents to reach them, rather than wholly taking the products off of the
market or imposing the costly burden that is a PMTA. A major step towards this
has already been accomplished with the nationwide T21 laws enacted on December
20, 2019, amending the FDCA by raising the minimum legal age for tobacco products from 18 years-old to 21 years-old.103 Prior to the amendment, nineteen states
raised the state-wide minimum legal age for tobacco products to 21, with Hawaii
and California being the first to implement T21 laws on January 1, 2016, and June
9, 2016, respectively.104 Although it is too early to know the substantive effects of
the FDCA amendment, the results of the state-led T21 laws have been mixed. The
98. Id. at 1832.
99. Vergano, supra note 47.
100. See infra notes 105-113 and accompanying text.
101. See Angelica LaVito, FDA may consider over-the-counter regulation for e-cigarettes, CNBC
(Mar. 28, 2018 10:16 AM), https://www.cnbc.com/2018/03/28/fda-may-consider-over-the-counter-regulation-for-e-cigarettes.html.
102. Id.
103. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 906(d), Pub. L. No. 111-31., 123 Stat. 1807
(1938) (codified as amended at 21 U.S.C. § 387f(d)(3)(A)(ii) (2019).
104. CTR. FOR DISEASE CONTROL, Tobacco 21: Policy Evaluation for Comprehensive Tobacco Control Programs 4-5, https://www.cdc.gov/tobacco/stateandcommunity/tobacco_control_programs/surveillance_evaluation/tobacco-21-policy-evaluation/pdfs/T21-policy-evaluation-guide-508.pdf (last visited April 2, 2021); Xueying Zhang, et al., Evaluation of California’s ‘Tobacco 21’ law, TOBACCO
CONTROL 2018:27:656, 656 (2018).
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results of a study published January 13, 2020 revealed that “[f]ollowing the T21 in
Hawaii, average monthly cigarette unit sales dropped significantly (−4.4%, p<0.01)
coupled with a significant decrease in menthol market share (−0.8, p<0.01),” and
concluded that “[a]s part of a comprehensive approach to prevent or delay tobacco
use initiation, T21 laws may help to reduce sales of cigarette and large cigar products most preferred by US youth and young adults.”105 These results are not across
the board, however, as a February 27, 2020 study on the effects of the T21 laws in
California found “[n]egligible changes in cigarette and e-cigarette use. . . observed
pre-T21 versus post-T21,” and concluded that “[p]ost-T21, few participants were
refused purchase of any tobacco product, despite the illegality of such sales. Better
enforcement of T21 is needed to improve the efficacy of T21 legislation.”106 As the
long-term effects of T21 laws are not yet certain, further limitations need to be implemented in the distribution of ENDS to reduce the availability of the products to
minors before additional flavored ENDS, which are favored by both adolescents
and adults attempting to quit traditional cigarettes, should reach the market. 107 If
classified as an OTC product, there is already the groundwork for a model distribution method for ENDS as a cessation device rather than a tobacco product in the
distribution limitations that the FDA placed on Nicorette (nicotine gum) during their
switch from prescription drug to OTC. 108 The FDA restricted the sale of Nicorette
to drugstores, mass merchandisers, and supermarkets, and prohibited its sale in convenience stores such as gas stations.109 The FDA also required the company to not
sell “trial size” or “sample” packs, package each piece of gum in child resistant
packaging, offer incentives to retailers to place Nicorette with the other OTC drugs,
and provide a smoking cessation program in the form of a toll-free phone number
on the packaging.110
For ENDS products, the limitations of restricting the sale to drugstores, mass
merchandisers, and supermarkets, and prohibiting their sale in conveniences stores,
coupled with a limitation on the online sales of the products, would arguably have
the greatest impact in keeping the products out of reach for adolescents. In 2019,
three-fourths of adolescents who used Juul, the most commonly sold e-cigarette
brand, obtained the product at a physical retail location, and approximately half of
all e-cigarette sales in the United States were through vape shops111 or the
105. Rebecca Glover-Kudon, et al., Cigarette and cigar sales in Hawaii before and after implementation of a Tobacco 21 Law, TOBACCO CONTROL 2021:30:98, 98 (2021).
106. Sara Schiff, et al., E-cigarette and cigarette purchasing among young adults before and after implantation of California’s tobacco 21 policy, TOBACCO CONTROL 2021:30:206, 206 (2021).
107. Gravely, supra note 51, at 1831.
108. See letter from Debra L. Bowen, M.D., Acting Director, Division of Over-the Counter Drug Products, and Cynthia G. McCormick, M.D., Director, Division of Anesthetic, Critical Care, and Addiction
Drug Products, to David Schifkovitz, Associate Director, Regulatory Affairs, SmithKline Beecham Consumer Healthcare (Dec. 23, 1998), https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18612S025_Nicorette_Approv.pdf (OTC approval letter to Nicorette that places marketing limitations on
the product).
109. See id.
110. See id.
111. A “Vape Shop” is a physical retail store that “sells products such as vape pens, tanks, mods, ejuices, e-hookahs, advanced systems, and their accompanying components along with e-liquid solutions
or cartridges. These stores may or may not have a vaping lounge or vaping bar inside as well. Many vape
shops operate on non-traditional retail hours, opening closer to noon and closing later at night.” See ECigarettes at the Point of Sale, COUNTER TOBACCO, https://countertobacco.org/resources-tools/evidence-summaries/e-cigarettes-at-the-point-of-sale/ (last visited April 2, 2021) [hereinafter E-Cigarettes
at the Point of Sale].
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internet.112 A 2018 study showed that, in California, tobacco and vape shops had
the highest rate of sales of vape products to underage adolescent decoys than any
other retailer type at 44.7%.113 Internet retail poses a similar problem, where a significant number of middle and high schoolers obtained their e-cigarettes online,114
and a 2015 study finding that “minors successfully received deliveries of e-cigarettes from 76.5% of purchase attempts, with no attempts by delivery companies to
verify their ages at delivery.”115 Conversely, according to the same 2018 California
study, pharmacies had the lowest failure to check identification for e-cigarettes rate
at approximately 10%, and small markets and supermarkets had the lowest violation
rate for underage e-cigarettes at approximately 12%.116 As such, placing distribution limitations on ENDS similar to those that are already placed on Nicorette,
which restricts the sales of the product to drug stores, mass merchandisers, and supermarkets, combined with the T-21 laws and the prohibition of online sales of
ENDS, would likely have a large beneficial impact in keeping the products out of
the hands of adolescents.

C. ENDS and Nicotine Abstinence
The overall goal of ENDS as cessation tools would be complete abstinence
from nicotine, rather than trading one addiction for another. To be an effective tool
for eventual nicotine abstinence, the addictiveness of ENDS would need to be comparable to other NRTs such as nicotine gum or transdermal nicotine patches, and
less addictive than traditional tobacco products.117 There does not seem to be a general consensus in the scientific community yet as to whether using ENDS as a cigarette cessation tool leads to a continuing dependence on nicotine.118

D. Barriers to ENDS as an Over-the-Counter Drug
Perhaps the largest obstacle for ENDS to be given an OTC monograph is that
they would first have to be generally regarded as safe and effective (“GRASE”)
before they can be given a monograph, and it may not be enough that they are both
generally regarded to be safer than traditional cigarettes and have shown to be a
better cigarette cessation tool than current NRTs.119 For a drug to be considered
GRASE:
112. See Fatma Romeh, et al., E-cigarette Unit Sales, by Product and Flavor Type — United States,
2014–2020, 69 MORBIDITY & MORTALITY WEEKLY REPORT 1313, 1316 (Sep. 18, 2020).
113. E-Cigarettes at the Point of Sale, supra note 111.
114. Where do Youth get their E-Cigarettes?, TOBACCO FREE KIDS, https://www.tobaccofreekids.org/assets/factsheets/0403.pdf (last visited April 2, 2021).
115. Rebecca S. Williams, et al., Electronic Cigarette Sales to Minors via the Internet, JAMA
PREDIATR. 2015:169(3):e1563, 1563 (March 2, 2015), https://jamanetwork.com/journals/jamapediatrics/article-abstract/2174572.
116. E-Cigarettes at the Point of Sale, supra note 111.
117. See generally Chowdhury & Jockel, supra note 85 (explaining the NRT process).
118. See generally e.g. Chen, at al., Use of Electronic Cigarettes to Aid Long-Term Smoking Cessation
in the United States: Prospective Evidence From the PATH Cohort Study, AM. J. OF EPIDEMIOLOGY
2020:189(12): 1529, 1529 (July 2020) (concluding that ENDS “may contribute to continuing nicotine
dependence.”); Guodong Liu, et al., A Comparison of Nicotine Dependence among Exclusive E-cigarette
and Cigarette Users in the PATH Study, PREV. MED. November:104:86, 86 (2017) (that “everyday exclusive e-cig users report lower dependence than comparable cigarette users.”).
119. See Chowdhury & Jockel, supra note 85; Hajek, supra note 50, at 629.
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First, the particular drug product must have been subjected to adequate and
well-controlled clinical investigations that establish the product as safe and effective.
Second, those investigations must have been published in the scientific literature available to qualified experts.
Third, experts must generally agree, based on those published studies, that the
product is safe and effective for its intended uses. At a minimum, the general acceptance of a product as GRASE must be supported by the same quality and quantity of scientific and/or clinical data necessary to support the approval of a New
Drug Application.120
Requiring the same amount and quality of data as an NDA is a high bar, and
an issue with ENDS lies in the relative recentness with which they appeared on the
market.121 The other OTC smoking cessation products, nicotine gum, nicotine lozenges, and nicotine patches, have all been on the market much longer than ENDS,
with nicotine lozenges, approved in 2002, being the most recent.122 ENDS products
have only been on the market since 2007, and there is still a great amount of uncertainty over the long-term effects of the products.123 Also, as mentioned above, an
NDA may be prohibitively expensive for more ENDS manufacturers.124 As the vast
majority of ENDS manufacturers would not be able to afford this process, either
one of the top ENDS manufacturers (who are likely the least affected by the PMTA
requirements) would need to make the request to the FDA and collect the data, or
the FDA would need to initiate the process on their own accord through an administrative order.125

IV.

CONCLUSION

An OTC monograph for ENDS would allow manufacturers to market the products to their full potential as cessation devices for a low cost, would make ENDS
accessible for adults while also providing a barrier against underage use, and would
allow for more regulatory oversight as to the safety of the products. Providing another safe tool to help the millions of American’s overcome their addiction to traditional cigarettes, while preventing nonsmokers and adolescents from developing
a nicotine addiction, should be among the top priorities of the United States. Although cigarette smoking rates in the United States have decreased from 20.9% in
2005, to 14.0% in 2019, it is still the leading cause of preventable deaths at 480,000
a year.126 Nicotine is among the most addictive substances in the world, and in 2018
only 7.5% of the 34.2 million Americans that smoked cigarettes managed to quit
successfully.127
120. U.S. FOOD & DRUG ADMIN., GRASE, https://www.accessdata.fda.gov/scripts/cder/training/otc/topic3/topic3/da_01_03_0040.htm (last visited April 2, 2021).
121. See Grana et al., supra note 40.
122. See Chowdhury & Jockel, supra note 85.
123. See Grana et al., supra note 40; Stratton, supra note 43, at 21.
124. See supra notes 63-67 and accompanying text.
125. See generally Drug Monograph Process, supra note 77.
126. CTR. FOR DISEASE CONTROL, Current Cigarette Smoking Among Adults in the United States (last
updated Dec. 10, 2020), https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm.
127. 5 Most Addictive Drugs, AMERICAN ADDICTION CENTERS, https://americanaddictioncenters.org/adult-addiction-treatment-programs/most-addictive (last updated Feb. 22, 2021); CTR. FOR
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ENDS have the potential to be the most effective cigarette cessation tool on the
market, and even under pessimistic models of long-term health effects, the complete
replacement of traditional cigarettes with ENDS would save approximately 1.6 million lives over a 20-year period.128 The current pathways to market for the products,
however, do not allow ENDS to live up to this life-saving potential. The available
tobacco pathway for ENDS, PMTA’s, limit the manufacturers to not allow them to
market the products as cessation devices. If the manufacturer wants to market their
ENDS product as a cessation tool, they must complete an NDA, which is much too
expensive, and would only allow for ENDS products to be sold with a prescription,
severely limiting their accessibility. Perhaps the largest barrier to ENDS obtaining
an OTC monograph is the lack of a scientific consensus on the long-term health
effects of the products.129 Paradoxically, an OTC monograph would give the FDA
more oversight in the research of the products.130 Regardless, the scientific consensus on ENDS products is that they are overall safer than traditional cigarettes, and
any step towards safely decreasing the number of traditional tobacco users in the
United States is a step that should be taken.131

DISEASE CONTROL, Smoking & Tobacco Use: Smoking Cessation: Fast Facts, https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/smoking-cessation-fast-facts/index.html (last updated May
21, 2020); CTR. FOR DISEASE CONTROL, Smoking & Tobacco Use: Fast Facts, https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm#cigarette-smoking (last updated May 21, 2020).
128. See Levy, supra note 43, at 18.
129. See Stratton, supra note 43, at 21.
130. See LaVito, supra note 101.
131. Stratton, supra note 43, at 12 (“[t]he evidence about harm reduction suggests that across a range
of studies and outcomes, e-cigarettes pose less risk to an individual than combustible tobacco cigarettes.”).
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